{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:24:18Z","timestamp":1778570658620,"version":"3.51.4"},"reference-count":101,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Familial hypercholesterolemia is characterized by high LDL cholesterol and an elevated risk to develop coronary heart disease. Mutations in LDL receptor-mediated cholesterol uptake are the main cause of familial hypercholesterolemia. However, multiple mutations in various other genes are also associated with high LDL cholesterol and even familial hypercholesterolemia. Thus, pharmaceuticals that target these genes and proteins might be attractive treatment options to reduce LDL cholesterol. This review provides an overview of the recent developments and clinical testing of such pharmaceuticals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>About 80 genes are associated with hypercholesterolemia but only pharmaceuticals that inhibit cholesteryl ester transfer protein (CETP), angiopoietin-related protein 3 (ANGPTL3), and apolipoprotein C-III (apoC-III) have recently been tested in clinical trials. Inhibition of CETP and ANGPTL3 lowered LDL cholesterol. ANGPTL3 inhibition had the largest effect and was even effective in familial hypercholesterolemia patients. The effect of apoC-III inhibition on LDL cholesterol is not conclusive.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Of the many potential pharmaceutical targets involved in LDL cholesterol, only a few have been studied so far. Of these, pharmaceuticals that inhibit CETP or ANGPTL3 are promising novel treatment options to reduce LDL cholesterol but the effect of apoC-III inhibition requires more research.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000489","type":"journal-article","created":{"date-parts":[[2018,1,21]],"date-time":"2018-01-21T02:34:33Z","timestamp":1516502073000},"page":"80-86","source":"Crossref","is-referenced-by-count":5,"title":["Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals?"],"prefix":"10.1097","volume":"29","author":[{"given":"Andrea","family":"Volta","sequence":"first","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands"},{"name":"Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Grefhorst","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands"},{"name":"Section of Endocrinology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1093\/eurheartj\/ehv289","article-title":"Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes","volume":"36","author":"Nanchen","year":"2015","journal-title":"Eur Heart J"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","article-title":"Mutations causative of familial hypercholesterolaemia: screening of 98,098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217","volume":"37","author":"Benn","year":"2016","journal-title":"Eur Heart J"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature13917","article-title":"Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction","volume":"518","author":"Do","year":"2014","journal-title":"Nature"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/HCO.0000000000000385","article-title":"Molecular basis of familial hypercholesterolemia","volume":"32","author":"Bruikman","year":"2017","journal-title":"Curr Opin Cardiol"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S0022-2275(20)30267-4","article-title":"Structure of apolipoprotein B-100 in low density lipoproteins","volume":"42","author":"Segrest","year":"2001","journal-title":"J Lipid Res"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1161\/CIRCGENETICS.112.963587","article-title":"Low prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort","volume":"5","author":"Ahmad","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ajhg.2014.01.010","article-title":"Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol","volume":"94","author":"Lange","year":"2014","journal-title":"Am J Hum Genet"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12944-017-0488-4","article-title":"Genetic determinants of inherited susceptibility to hypercholesterolemia \u2013 a comprehensive literature review","volume":"16","author":"Paththinige","year":"2017","journal-title":"Lipids Health Dis"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"339","DOI":"10.7326\/M14-0126","article-title":"Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology\/American Heart Association Cholesterol Guideline","volume":"160","author":"Stone","year":"2014","journal-title":"Ann Intern Med"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: Part 1 \u2013 Full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCGENETICS.108.773168","article-title":"Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and apolipoprotein B among 6382 white women in genome-wide analysis with replication","volume":"1","author":"Chasman","year":"2008","journal-title":"Circ Cardiovasc Genet"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/ng.75","article-title":"Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans","volume":"40","author":"Kathiresan","year":"2008","journal-title":"Nat Genet"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.269","article-title":"Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts","volume":"41","author":"Aulchenko","year":"2009","journal-title":"Nat Genet"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.numecd.2012.04.012","article-title":"Discontinuation of statin therapy due to muscular side effects: a survey in real life","volume":"23","author":"Rosenbaum","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2013 the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1388-1981(99)00083-9","article-title":"Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver","volume":"1440","author":"Davis","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.med.55.091902.104408","article-title":"Progress in antisense technology","volume":"55","author":"Crooke","year":"2004","journal-title":"Annu Rev Med"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","article-title":"Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B","volume":"114","author":"Kastelein","year":"2006","journal-title":"Circulation"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjcard.2010.01.003","article-title":"Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia","volume":"105","author":"Akdim","year":"2010","journal-title":"Am J Cardiol"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2017.02.019","article-title":"Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study)","volume":"259","author":"Waldmann","year":"2017","journal-title":"Atherosclerosis"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosissup.2015.02.005","article-title":"Mipomersen and lomitapide: two new drugs for the treatment of homozygous familial hypercholesterolemia","volume":"18","author":"Gouni-Berthold","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"R30-20230917","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"R31-20230917","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R32-20230917","first-page":"69","article-title":"Lipoprotein(a): biology and clinical importance","volume":"25","author":"McCormick","year":"2004","journal-title":"Clin Biochem Rev"},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur Heart J"},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J Biol Chem"},{"key":"R36-20230917","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R37-20230917","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00041433-200106000-00006","article-title":"Living up to a name: the role of the VLDL receptor in lipid metabolism","volume":"12","author":"Tacken","year":"2001","journal-title":"Curr Opin Lipidol"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.atherosclerosis.2017.01.015","article-title":"Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France","volume":"257","author":"Bruckert","year":"2017","journal-title":"Atherosclerosis"},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R43-20230917","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"R44-20230917","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1194\/jlr.R024075","article-title":"Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk","volume":"53","author":"Barter","year":"2012","journal-title":"J Lipid Res"},{"key":"R45-20230917","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1001\/jama.299.23.2777","article-title":"Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk","volume":"299","author":"Thompson","year":"2008","journal-title":"JAMA"},{"key":"R46-20230917","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/clpt.2014.85","article-title":"An overview of the new frontiers in the treatment of atherogenic dyslipidemias","volume":"96","author":"Rached","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"R47-20230917","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"R48-20230917","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"R49-20230917","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"R50-20230917","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"R51-20230917","first-page":"70","article-title":"Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans","volume":"119","author":"Romeo","year":"2008","journal-title":"J Clin Invest"},{"key":"R52-20230917","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/MOL.0000000000000290","article-title":"Regulation of lipid metabolism by angiopoietin-like proteins","volume":"27","author":"Dijk","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"R53-20230917","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1042\/BST0331059","article-title":"Regulation of lipid metabolism via angiopoietin-like proteins","volume":"33","author":"Kersten","year":"2005","journal-title":"Biochem Soc Trans"},{"key":"R54-20230917","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbalip.2014.03.013","article-title":"Physiological regulation of lipoprotein lipase","volume":"1841","author":"Kersten","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"R55-20230917","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1258\/acb.2010.009307","article-title":"Association of angiopoietin-like protein 3 with hepatic triglyceride lipase and lipoprotein lipase activities in human plasma","volume":"47","author":"Nakajima","year":"2010","journal-title":"Ann Clin Biochem"},{"key":"R56-20230917","doi-asserted-by":"crossref","first-page":"33742","DOI":"10.1074\/jbc.M203215200","article-title":"ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase","volume":"277","author":"Shimizugawa","year":"2002","journal-title":"J Biol Chem"},{"key":"R57-20230917","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1538\/expanim.55.27","article-title":"Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity","volume":"55","author":"Fujimoto","year":"2006","journal-title":"Exp Anim"},{"key":"R58-20230917","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/01.ATV.0000252827.51626.89","article-title":"Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase","volume":"27","author":"Shimamura","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R59-20230917","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-015-0838-9","article-title":"The role of ANGPTL3 in controlling lipoprotein metabolism","volume":"52","author":"Tikka","year":"2016","journal-title":"Endocrine"},{"key":"R60-20230917","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N Engl J Med"},{"key":"R61-20230917","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-1298","article-title":"Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization","volume":"97","author":"Minicocci","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R62-20230917","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/CIRCGENETICS.111.960674","article-title":"Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3","volume":"5","author":"Pisciotta","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"R63-20230917","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1161\/ATVBAHA.111.238766","article-title":"Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia","volume":"32","author":"Noto","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R64-20230917","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cca.2011.11.020","article-title":"Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation","volume":"413","author":"Mart\u00edn-Campos","year":"2012","journal-title":"Clin Chim Acta"},{"key":"R65-20230917","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ng.3561","article-title":"Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease","volume":"48","author":"Helgadottir","year":"2016","journal-title":"Nat Genet"},{"key":"R66-20230917","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys","volume":"56","author":"Gusarova","year":"2015","journal-title":"J Lipid Res"},{"key":"R67-20230917","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1194\/jlr.M054882","article-title":"Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion","volume":"56","author":"Wang","year":"2015","journal-title":"J Lipid Res"},{"key":"R68-20230917","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1194\/jlr.M300031-JLR200","article-title":"A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice","volume":"44","author":"Ando","year":"2003","journal-title":"J Lipid Res"},{"key":"R69-20230917","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1161\/01.ATV.20.5.1309","article-title":"In vivo metabolism of ApoB, ApoA-I, and VLDL triglycerides in a form of hypobetalipoproteinemia not linked to the ApoB gene","volume":"20","author":"Elias","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R70-20230917","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R71-20230917","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"R72-20230917","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N Engl J Med"},{"key":"R73-20230917","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N Engl J Med"},{"key":"R74-20230917","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","article-title":"Apolipoprotein C-III: understanding an emerging cardiovascular risk factor","volume":"114","author":"Ooi","year":"2008","journal-title":"Clin Sci"},{"key":"R75-20230917","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0022-2275(20)37316-8","article-title":"Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects","volume":"22","author":"Huff","year":"1981","journal-title":"J Lipid Res"},{"key":"R76-20230917","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0021-9150(88)90288-2","article-title":"Metabolism of apolipoprotein C-III in normolipemic human subjects","volume":"69","author":"Malmendier","year":"1988","journal-title":"Atherosclerosis"},{"key":"R77-20230917","doi-asserted-by":"crossref","first-page":"33997","DOI":"10.1074\/jbc.M113.495366","article-title":"Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets","volume":"288","author":"Larsson","year":"2013","journal-title":"J Biol Chem"},{"key":"R78-20230917","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1194\/jlr.M078220","article-title":"Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL","volume":"58","author":"Larsson","year":"2017","journal-title":"J Lipid Res"},{"key":"R79-20230917","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"key":"R80-20230917","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"R81-20230917","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"key":"R82-20230917","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11883-016-0609-y","article-title":"Targeting ApoC-III to reduce coronary disease risk","volume":"18","author":"Khetarpal","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"R83-20230917","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ Res"},{"key":"R84-20230917","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"key":"R85-20230917","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"key":"R86-20230917","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc16-0126","article-title":"Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes","volume":"39","author":"Digenio","year":"2016","journal-title":"Diabetes Care"},{"key":"R87-20230917","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9149(03)00721-5","article-title":"Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol","volume":"92","author":"Bays","year":"2003","journal-title":"Am J Cardiol"},{"key":"R88-20230917","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jacl.2016.08.002","article-title":"Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients","volume":"10","author":"Stein","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R89-20230917","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fendo.2014.00004","article-title":"Angiopoietin-like proteins: a comprehensive look","volume":"5","author":"Santulli","year":"2014","journal-title":"Front Endocrinol"},{"key":"R90-20230917","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/ng1984","article-title":"Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL","volume":"39","author":"Romeo","year":"2007","journal-title":"Nat Genet"},{"key":"R91-20230917","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ymgme.2016.04.007","article-title":"The Arg59Trp variant in ANGPTL8 (betatrophin) is associated with total and HDL-cholesterol in American Indians and Mexican Americans and differentially affects cleavage of ANGPTL3","volume":"118","author":"Hanson","year":"2016","journal-title":"Mol Genet Metab"},{"key":"R92-20230917","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.molmet.2017.06.014","article-title":"ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase","volume":"6","author":"Chi","year":"2017","journal-title":"Mol Metab"},{"key":"R93-20230917","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1194\/jlr.M075689","article-title":"ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance","volume":"58","author":"Haller","year":"2017","journal-title":"J Lipid Res"},{"key":"R94-20230917","doi-asserted-by":"crossref","first-page":"e16604","DOI":"10.1371\/journal.pone.0016604","article-title":"Variation in LPA is associated with Lp(a) levels in three populations from the Third National Health and Nutrition Examination Survey","volume":"6","author":"Dumitrescu","year":"2011","journal-title":"PLoS One"},{"key":"R95-20230917","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jacc.2012.04.038","article-title":"Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies","volume":"60","author":"Tsimikas","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R96-20230917","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/01.hjr.0000087080.83314.be","article-title":"Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease","volume":"10","author":"Imhof","year":"2003","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"R97-20230917","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"R98-20230917","doi-asserted-by":"crossref","first-page":"19720","DOI":"10.1074\/jbc.M110.123729","article-title":"The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2","volume":"285","author":"Hong","year":"2010","journal-title":"J Biol Chem"},{"key":"R99-20230917","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1373\/clinchem.2009.134023","article-title":"New Idol for cholesterol reduction?","volume":"55","author":"Sawamura","year":"2009","journal-title":"Clin Chem"},{"key":"R100-20230917","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.mehy.2015.11.010","article-title":"IDOL, inducible degrader of low-density lipoprotein receptor, serves as a potential therapeutic target for dyslipidemia","volume":"86","author":"Zhang","year":"2016","journal-title":"Med Hypotheses"},{"key":"R101-20230917","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/ATVBAHA.116.307808","article-title":"Translational and therapeutic approaches to the understanding and treatment of dyslipidemia","volume":"36","author":"Zhang","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201804000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T08:17:05Z","timestamp":1694938625000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201804000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000489","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}